SHITAL PATEL to Adult
This is a "connection" page, showing publications SHITAL PATEL has written about Adult.
Connection Strength
0.173
-
Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes. J Infect Dis. 2012 Oct 01; 206(7):1069-77.
Score: 0.017
-
A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route. Vaccine. 2010 Apr 09; 28(17):3025-9.
Score: 0.014
-
Safety and immunogenicity of three seasonal inactivated influenza vaccines among pregnant women and antibody persistence in their infants. Vaccine. 2020 07 14; 38(33):5355-5363.
Score: 0.007
-
Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial. PLoS One. 2019; 14(9):e0222178.
Score: 0.007
-
A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area. Vaccine. 2019 10 08; 37(43):6500-6509.
Score: 0.007
-
Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination. Vaccine. 2019 05 01; 37(19):2561-2568.
Score: 0.007
-
Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women. Vaccine. 2018 12 18; 36(52):8054-8061.
Score: 0.007
-
Sources of clinical information used in HIV care and treatment: Are providers' choices related to their demographic and practice characteristics? Health Informatics J. 2019 12; 25(4):1572-1587.
Score: 0.006
-
Innate, T-, and B-Cell Responses in Acute Human Zika Patients. Clin Infect Dis. 2018 01 06; 66(1):1-10.
Score: 0.006
-
Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial. Vaccine. 2017 08 24; 35(36):4730-4737.
Score: 0.006
-
Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial. Vaccine. 2017 03 23; 35(13):1675-1682.
Score: 0.006
-
Prolonged Detection of Zika Virus in Vaginal Secretions and Whole Blood. Emerg Infect Dis. 2017 01; 23(1):99-101.
Score: 0.006
-
Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination. J Infect Dis. 2016 10 01; 214(7):1020-9.
Score: 0.006
-
Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine. Vaccine. 2016 Jan 20; 34(4):547-554.
Score: 0.005
-
Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant. Clin Vaccine Immunol. 2016 01; 23(1):73-7.
Score: 0.005
-
Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. JAMA. 2015 Jul 21; 314(3):237-46.
Score: 0.005
-
DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial. PLoS One. 2015; 10(5):e0125914.
Score: 0.005
-
Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine. J Infect Dis. 2015 Aug 15; 212(4):525-30.
Score: 0.005
-
Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons =18 Years Old. J Infect Dis. 2015 Aug 15; 212(4):552-61.
Score: 0.005
-
Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. Vaccine. 2015 Jan 01; 33(1):163-73.
Score: 0.005
-
Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults. Vaccine. 2014 Oct 29; 32(47):6284-93.
Score: 0.005
-
A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PLoS One. 2012; 7(12):e49704.
Score: 0.004
-
Picornavirus, the most common respiratory virus causing infection among patients of all ages hospitalized with acute respiratory illness. J Clin Microbiol. 2012 Feb; 50(2):506-8.
Score: 0.004
-
Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women. J Infect Dis. 2011 Sep 15; 204(6):854-63.
Score: 0.004
-
Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine. Vaccine. 2011 Oct 19; 29(45):8066-72.
Score: 0.004
-
Association of apolipoprotein E genotype with duration of time to achieve a stable warfarin dose in African-American patients. Pharmacotherapy. 2011 Aug; 31(8):785-92.
Score: 0.004
-
Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults. Vaccine. 2009 Nov 05; 27(47):6642-8.
Score: 0.003
-
Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis. 2008 Nov 01; 198(9):1309-16.
Score: 0.003
-
Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis. 2006 Nov 01; 43(9):1135-42.
Score: 0.003